Oncogene-induced senescence as an initial barrier in lymphoma development

被引:966
作者
Braig, M
Lee, S
Loddenkemper, C
Rudolph, C
Peters, AHFM
Schlegelberger, B
Stein, H
Dörken, B
Jenuwein, T
Schmitt, CA [1 ]
机构
[1] Charite Univ Med Berlin Haematol Oncol, D-13353 Berlin, Germany
[2] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany
[3] Res Inst Mol Pathol, A-1030 Vienna, Austria
[4] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland
[5] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany
[6] Charite Univ Med Berlin, Dept Pathol, D-12200 Berlin, Germany
关键词
D O I
10.1038/nature03841
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Acute induction of oncogenic Ras provokes cellular senescence involving the retinoblastoma (Rb) pathway, but the tumour suppressive potential of senescence in vivo remains elusive. Recently, Rb-mediated silencing of growth-promoting genes by heterochromatin formation associated with methylation of histone H3 lysine 9 (H3K9me) was identified as a critical feature of cellular senescence, which may depend on the histone methyltransferase Suv39h1. Here we show that E mu-N-Ras transgenic mice harbouring targeted heterozygous lesions at the Suv39h1, or the p53 locus for comparison, succumb to invasive T-cell lymphomas that lack expression of Suv39h1 or p53, respectively. By contrast, most N-Ras-transgenic wild-type ('control') animals develop a non-lymphoid neoplasia significantly later. Proliferation of primary lymphocytes is directly stalled by a Suv39h1-dependent, H3K9me-related senescent growth arrest in response to oncogenic Ras, thereby cancelling lymphomagenesis at an initial step. Suv39h1-deficient lymphoma cells grow rapidly but, unlike p53-deficient cells, remain highly susceptible to adriamycin-induced apoptosis. In contrast, only control, but not Suv39h1-deficient or p53-deficient, lymphomas senesce after drug therapy when apoptosis is blocked. These results identify H3K9me-mediated senescence as a novel Suv39h1-dependent tumour suppressor mechanism whose inactivation permits the formation of aggressive but apoptosis-competent lymphomas in response to oncogenic Ras.
引用
收藏
页码:660 / 665
页数:6
相关论文
共 31 条
[1]   A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells [J].
Ait-Si-Ali, S ;
Guasconi, V ;
Fritsch, L ;
Yahi, H ;
Sekhri, R ;
Naguibneva, I ;
Robin, P ;
Cabon, F ;
Polesskaya, A ;
Harel-Bellan, A .
EMBO JOURNAL, 2004, 23 (03) :605-615
[2]   Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain [J].
Bannister, AJ ;
Zegerman, P ;
Partridge, JF ;
Miska, EA ;
Thomas, JO ;
Allshire, RC ;
Kouzarides, T .
NATURE, 2001, 410 (6824) :120-124
[3]   Cellular senescence as a tumor-suppressor mechanism [J].
Campisi, J .
TRENDS IN CELL BIOLOGY, 2001, 11 (11) :S27-S31
[4]  
Chang BD, 1999, CANCER RES, V59, P3761
[5]   A BIOMARKER THAT IDENTIFIES SENESCENT HUMAN-CELLS IN CULTURE AND IN AGING SKIN IN-VIVO [J].
DIMRI, GP ;
LEE, XH ;
BASILE, G ;
ACOSTA, M ;
SCOTT, C ;
ROSKELLEY, C ;
MEDRANO, EE ;
LINSKENS, M ;
RUBELJ, I ;
PEREIRASMITH, O ;
PEACOCKE, M ;
CAMPISI, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (20) :9363-9367
[6]   Tumor cells escape suicide gene therapy by genetic and epigenetic instability [J].
Frank, O ;
Rudolph, C ;
Heberlein, C ;
von Neuhoff, N ;
Schröck, E ;
Schambach, A ;
Schlegellberger, B ;
Fehse, B ;
Ostertag, W ;
Stocking, C ;
Baum, C .
BLOOD, 2004, 104 (12) :3543-3549
[7]   The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase [J].
Fuks, F ;
Hurd, PJ ;
Deplus, R ;
Kouzarides, T .
NUCLEIC ACIDS RESEARCH, 2003, 31 (09) :2305-2312
[8]   Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context [J].
Guerra, C ;
Mijimolle, N ;
Dhawahir, A ;
Dubus, P ;
Barradas, M ;
Serrano, M ;
Campuzano, V ;
Barbacid, M .
CANCER CELL, 2003, 4 (02) :111-120
[9]   T cell receptor gene rearrangement lineage analysis reveals clues for the origin of highly restricted antigen-specific repertoires [J].
Hamrouni, A ;
Aublin, A ;
Guillaume, P ;
Maryanski, JL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (05) :601-614
[10]  
HAUPT Y, 1992, ONCOGENE, V7, P981